Search
Meet Fabienne Lucas, our January Volunteer of the Month
EHA is a Public Benefit Organization under Dutch law.
Read moreTargeting the B-cell Receptor in Aggressive B-cell Lymphomas
In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.
Read moreEHA-ECL led statement calls for protection of the Hospital Exemption
The hospital exemption (HE) is a vital provision within the EU's pharmaceutical legislation, currently subject to a revision.
Read moreCelebrating the International Day of Women & Girls in Science
On this International Day of Women & Girls in Science, we take a moment to honor, appreciate and thank, all the women scientists at the forefront of the fight against COVID-19.
Read moreMoldova to be allowed to participate in EU4Health projects
The European Commission and the Government of the Republic of Moldova have signed an agreement to associate Moldova with the EU4Health program.
Read moreTARGETING THE JAK-STAT PATHWAY IN MALIGNANT AND NON-MALIGNANT CELLS IN MYELOPROLIFERATIVE NEOPLASMS
Myeloproliferative neoplasms (MPN) are clonal blood disorders characterized by excessive production of mature blood cells. Patients present with large spleens, systemic symptoms, and high levels of circulating inflammatory cytokines.
Read more